Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909946 · ClinicalTrials.gov registry record · NA
Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
NCT02909946: Completed NA study, sponsored by University of Michigan.
NCT02909946 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 246 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02909946, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
Study Summary
Multidrug-resistant organisms (MDROs) are endemic in nursing homes (NHs) with prevalence rates surpassing those in hospitals. The aim of the study is to design and evaluate the effectiveness of a multi-component intervention to reduce new acquisition of MDROs in NH residents. The intervention will incorporate resident-level, environmental, and caregiver based strategies. Using a cluster-randomized study design, three NHs will be randomized to the intervention group and three to the control group. Control NHs will be allowed to continue standard infection prevention practices. Nursing homes will serve as the unit of allocation. Analyses will be performed both at the resident and the cluster level. The primary outcomes of the study are reduction in MDRO prevalence, and reduction in new MDRO acquisition .
Primary Outcome
Total number of MDROs isolated across all MDROs and all anatomic sites for all enrolled residents over the duration of the study period
Interventions
- BEHAVIORAL Multi-modal Infection Control Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2018-08-29 |
| Phase | NA |
What the finished NCT02909946 record still lists
NCT02909946 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Multi-modal Infection Control Program is the first listed.
NCT02909946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02909946 about?
NCT02909946 is a clinical study titled "Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents". Multidrug-resistant organisms (MDROs) are endemic in nursing homes (NHs) with prevalence rates surpassing those in hospitals. The aim of the study is to design and evaluate the effectiveness of a multi-component intervention to reduce new acquisition of MDROs in NH residents. The intervention will i...
What is the current status of trial NCT02909946?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2016-09-15. Estimated completion is 2018-08-29.
What interventions are being tested in trial NCT02909946?
The interventions under investigation include: Multi-modal Infection Control Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT02909946?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02909946's enrollment target sits among peer trials
246 436th of 2000 higher than 1,565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI